239 related articles for article (PubMed ID: 38533911)
1. The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets.
Wang J; Ouyang X; Zhu W; Yi Q; Zhong J
Cancer Control; 2024; 31():10732748241241162. PubMed ID: 38533911
[TBL] [Abstract][Full Text] [Related]
2. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.
Singh AK; Arya RK; Trivedi AK; Sanyal S; Baral R; Dormond O; Briscoe DM; Datta D
Cytokine Growth Factor Rev; 2013 Feb; 24(1):41-9. PubMed ID: 22989616
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.
Proost P; Mortier A; Loos T; Vandercappellen J; Gouwy M; Ronsse I; Schutyser E; Put W; Parmentier M; Struyf S; Van Damme J
Blood; 2007 Jul; 110(1):37-44. PubMed ID: 17363734
[TBL] [Abstract][Full Text] [Related]
4. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
[TBL] [Abstract][Full Text] [Related]
5. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
[TBL] [Abstract][Full Text] [Related]
6. Interactions of the chemokines CXCL11 and CXCL12 in human tumor cells.
Koch C; Fischer NC; Puchert M; Engele J
BMC Cancer; 2022 Dec; 22(1):1335. PubMed ID: 36539774
[TBL] [Abstract][Full Text] [Related]
7. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
8. NMR structure of CXCR3 binding chemokine CXCL11 (ITAC).
Booth V; Clark-Lewis I; Sykes BD
Protein Sci; 2004 Aug; 13(8):2022-8. PubMed ID: 15273303
[TBL] [Abstract][Full Text] [Related]
9. Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.
McColl SR; Mahalingam S; Staykova M; Tylaska LA; Fisher KE; Strick CA; Gladue RP; Neote KS; Willenborg DO
Lab Invest; 2004 Nov; 84(11):1418-29. PubMed ID: 15322564
[TBL] [Abstract][Full Text] [Related]
10. The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.
Reynders N; Abboud D; Baragli A; Noman MZ; Rogister B; Niclou SP; Heveker N; Janji B; Hanson J; Szpakowska M; Chevigné A
Cells; 2019 Jun; 8(6):. PubMed ID: 31216755
[TBL] [Abstract][Full Text] [Related]
11. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.
Burns JM; Summers BC; Wang Y; Melikian A; Berahovich R; Miao Z; Penfold ME; Sunshine MJ; Littman DR; Kuo CJ; Wei K; McMaster BE; Wright K; Howard MC; Schall TJ
J Exp Med; 2006 Sep; 203(9):2201-13. PubMed ID: 16940167
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation.
Flier J; Boorsma DM; van Beek PJ; Nieboer C; Stoof TJ; Willemze R; Tensen CP
J Pathol; 2001 Aug; 194(4):398-405. PubMed ID: 11523046
[TBL] [Abstract][Full Text] [Related]
13. Airway smooth muscle CXCR3 ligand production: regulation by JAK-STAT1 and intracellular Ca²⁺.
Tan X; Alrashdan YA; Alkhouri H; Oliver BG; Armour CL; Hughes JM
Am J Physiol Lung Cell Mol Physiol; 2013 Jun; 304(11):L790-802. PubMed ID: 23564506
[TBL] [Abstract][Full Text] [Related]
14. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
15. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
16. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
Xanthou G; Duchesnes CE; Williams TJ; Pease JE
Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
[TBL] [Abstract][Full Text] [Related]
17. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7.
Puchert M; Obst J; Koch C; Zieger K; Engele J
Cytokine; 2020 Jan; 125():154809. PubMed ID: 31437604
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.
Ludwig A; Schiemann F; Mentlein R; Lindner B; Brandt E
J Leukoc Biol; 2002 Jul; 72(1):183-91. PubMed ID: 12101279
[TBL] [Abstract][Full Text] [Related]
19. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
[TBL] [Abstract][Full Text] [Related]
20. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4
Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
